MedTrace Logo

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT01144260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-05-15

No results posted yet for this study

Summary

A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Conditions

  • B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

bafetinib

250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.

Sponsors & Collaborators

  • CytRx

    lead INDUSTRY

Principal Investigators

  • Daniel Levitt, M.D., Ph.D. · CytRx

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-12-31
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144260 on ClinicalTrials.gov